Mesenchymal stem cell-derived exosome uptake machinery (MSC-Exo uptake machinery)

Mesenchymal stem cell-derived exosome (MSC-Exo) uptake machinery refers to the complex suite of cell-surface receptors and endocytic pathways that facilitate the internalization of MSC-secreted extracellular vesicles by recipient cells. This machinery is not a single entity but a heterogeneous collection of proteins including heparan sulfate proteoglycans (HSPGs), integrins (e.g., CD29, CD44), tetraspanins (CD9, CD63, CD81), and lectins, which mediate the initial docking and binding of exosomes to the target cell surface (1.1.3, 1.2.2). Following attachment, exosomes are typically internalized via various endocytic routes, such as clathrin-mediated endocytosis, caveolae-dependent endocytosis, macropinocytosis, or direct membrane fusion (1.1.3, 1.2.2). This process is fundamental to the paracrine signaling of MSCs, allowing the delivery of bioactive cargos—including microRNAs, proteins, and lipids—that promote tissue regeneration, modulate immune responses, and inhibit apoptosis in target tissues (1.1.1, 1.4.2). In therapeutic contexts, this machinery is targeted to enhance the delivery of engineered exosomes or to study the mechanisms of MSC-based cell-free therapies (1.3.2, 1.3.3). Experimental inhibitors like heparin and dynasore are frequently used in research to characterize these pathways, though no specific drugs are currently approved to target this system in a clinical setting (1.2.2).

Other names

MSC-derived exosome internalization pathwaysMSC-Exo receptorsExosome endocytic machineryMSC-EV uptake systemMesenchymal stem cell-derived extracellular vesicle uptake machinery

Inhibition of endocytic pathways (clathrin-mediated, caveolae-dependent, or macropinocytosis) and competitive binding to surface proteoglycans or receptors to prevent exosome internalization.